

Endocrine Abstracts

May 2015 Volume 37
ISSN 1479-6848 (online)

17th European Congress of
Endocrinology 2015

16–20 May 2015, Dublin, Ireland



published by
bioscientifica

Online version available at
www.endocrine-abstracts.org



17th European Congress of Endocrinology

16–20 May 2015, Dublin, Ireland

EDITORS

The abstracts were marked by the Abstract Marking Panel selected by the Programme Organising Committee

ECE 2015 Programme Organising Committee

W Arlt Chair
J Visser Co-chair
F Beuschlein Co-chair

Members

P Beck-Peccoz	M Korbonits	N Pitteloud	M Sherlock
P Burman	M Laan	M Pfeifer	A Spada
J Christiansen	E Lalli	JA Romijn	M Tena-Sempere
M Hewison	D Marks	R Ross	C Thompson
I Huhtaniemi	J Mittag	D Schulte	
E Husebye	M Niedziela	R Semple	

Abstract Marking Panel

A Agha Ireland	L Duntas Greece	G Kaltsas Greece	G P Rossi Italy
M Alevizaki Greece	G Eisenhofer Germany	A Karlsson Sweden	M Ruchala Poland
B Allolio Germany	F Fallo Italy	F Kelestimur Turkey	M Sahin Turkey
J Argente Spain	P Farahani Canada	R Kineman USA	D Salvatore Italy
G Assié France	S Farooqi UK	H Krude Germany	S Sanlioglu Turkey
S Babajko France	M Fassnacht Germany	J Laven The Netherlands	P Saunders UK
K Badenhop Germany	R Feelders The Netherlands	G Lavery UK	M Schiffer Germany
D Bassett UK	U Feldt-Rasmussen Denmark	P Lips Netherlands	S Schmid Germany
E Baudin France	F Flamant France	A Luger Austria	P Schöffski Belgium
A Beckers Belgium	E Fliers The Netherlands	R M Luque Spain	J Schopohl Germany
A Berruti Italy	C Fluck Switzerland	M Maggi Italy	M Schott Germany
J Bertherat France	S Franks UK	J Magre France	R Sharpe UK
B Bilinska Poland	W Fraser UK	M Mannelli Italy	M Simoni Italy
M Bluher Germany	J Frystyk Denmark	F Mantero Italy	J Smit The Netherlands
K Boelaert UK	R Gärtner Germany	C McCabe UK	U Smith Sweden
A Boelen The Netherlands	A Gimenez-Roqueplo Spain	R Mitchell UK	E Stener-Victorin Sweden
R Bouillon Belgium	J Gomez-Ambrosi Spain	E Nagy Hungary	M Terzolo Italy
J-P Bourguignon Belgium	R Granata Italy	J Newell-Prize UK	M Theodoropoulou Germany
M L Brandi Italy	J Gromoll Germany	K Owen UK	P Thompson UK
K Briot France	A Grossman UK	M Paez-Pereda Germany	V Tillmann Estonia
G Brunetti Italy	S Hahner Germany	J J Palvimo Finland	H Timmers The Netherlands
C Buchanan UK	R Hampl Czech Republic	S Papopolous Netherlands	J Tomlinson UK
J S Carroll UK	S Herzig Germany	S Pearce UK	J Toppari Finland
J Castano Spain	A Hoeflich Germany	R Peeters The Netherlands	Z Toth Hungary
K Chatterjee UK	C Hofig Sweden	P Perros UK	S Tsagarakis Greece
B Chini Italy	J Hoffland Netherlands	L Persani Italy	M Tzanela Greece
I Chiodini Italy	W Höglger UK	M Pfeifer Slovenia	E Valassi Spain
J Chowen Spain	P Igaz Hungary	M Poutanen Finland	A J van der Lelij Netherlands
T Coll UK	S Inzucchi USA	D Power Portugal	W van Hul Belgium
C Daousi UK	E R Isenovic Serbia	V Prevot France	L van Rossum Netherlands
W de Herder Netherlands	M-L Jaffrain-Rea Italy	S Radian UK	V Volke Estonia
E de Koning The Netherlands	J Janssen Netherlands	E Rajpert-De Meyts Denmark	R Voutilainen Finland
R de Krijger The Netherlands	C Jazdzewski Poland	M Reincke Germany	I Wilkinson UK
W Dhillo UK	D Jezova Slovakia	S Rice UK	T Williams Italy
G Di Dalmazi Germany	N Jørgensen Denmark	M Robledo Spain	Z Wu Germany
E Diamanti-Kandarakis Greece	J Jürimäe Estonia	P Rodien France	J Young France
F Dotta Italy	A Juul Denmark	C Ronchi Italy	M Zatelli Italy
J Drouin Canada	A Kalsbeek Netherlands	R Ross UK	M Zennaro France

SPONSORS

The ESE would like to thank its Corporate Members and the ECE 2015 sponsors

ECE Corporate Members

Eli Lilly
Ipsen
Laboratoire HRA Pharma
Merck Serono (MSD)
Novartis Pharmaceuticals
Novo Nordisk
Pfizer
Sandoz International GmbH
ViroPharma SPRL

Gold Sponsors

Ipsen
Novartis Pharmaceuticals

Bronze Sponsors

MSD International GmbH



ESE Office

Euro House
22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK

Contact:
Tel:
Fax:
E-mail:
Web site:

Andrea Davis
+44 (0)1454 642247
+44 (0)1454 642222
info@euro-endo.org
www.es-hormones.org



ECE 2015 Secretariat

Bioscientifica Ltd
Euro House, 22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK

Contact:
Tel:
Fax:
E-mail:
Website:

Claire Arrigoni
+44 (0)1454 642240
+44 (0)1454 642222
conferences@bioscientifica.com
http://www.bioscientifica.com

CONTENTS

17th European Congress of Endocrinology 2015

PRIZE LECTURES AND BIOGRAPHICAL NOTES

The European Journal of Endocrinology Prize Lecture	EJE1
The Geoffrey Harris Prize Lecture	GH1

PLENARY LECTURES

PI 3-Kinase: connecting diabetes, obesity and cancer	PL1
European Hormone Medal Lecture: Obesity and insulin resistance: Lessons from human genetics	PL2
The genomics of adrenocortical tumors	PL3
Congenital Adrenal Hyperplasia (CAH): Mechanisms and management across the life span	PL4
Insulin signalling and action	PL5
Initiative for Science in Europe (ISE) - how can we lobby so that Europe listens?	PL6
Obesity and the skeleton	PL7
From base change to better care in diabetes	PL8

SYMPOSIA

Glucocorticoid action in health and disease	S1.1–S1.3
Management of type 2 diabetes: State of the art	S2.1–S2.3
Non-classical causes of hypopituitarism (<i>Endorsed by Endocrine Connections</i>)	S3.1–S3.3
Thyroid hormone and cardiovascular system	S4.1–S4.3
Endocrinology of ageing men	S5.1–S5.3
Beyond Phosphorus: multiple actions of FGF23	S6.1–S6.3
Novel mechanisms of central weight regulation	S7.1–S7.3
The endocrine gut (<i>Endorsed by Endocrine Connections</i>)	S8.1–S8.3
Steroid hormone action in target tissues	S9.1–S9.3
Thyroid and autoimmunity	S10.1–S10.3
Hot topics and IESP symposia	S11.1–S11.3
Advances in pheochromocytoma diagnosis and management (<i>Endorsed by the European Journal of Endocrinology</i>)	S12.1–S12.3
New concepts in Vitamin D research	S13.1–S13.4
Adipose tissue as an endocrine organ (<i>Endorsed by Endocrine Connections</i>)	S14.1–S14.3
Puberty: new mechanisms	S15.1–S15.3
Pathogenesis of adrenocortical tumours	S16.1–S16.3
Diabetes and bone (<i>Endorsed by the European Journal of Endocrinology</i>)	S17.1–S17.3
New genetics of pituitary tumours (<i>Endorsed by the European Journal of Endocrinology</i>)	S18.1–S18.3
Metabolic dysfunction in PCOS	S19.1–S19.3
Endocrine consequences of childhood cancer treatment	S20.1–S20.5
Thyroid hormone in pregnancy	S21.1–S21.3
Beta cell biology	S22.1–S22.3
Adrenal insufficiency: advances in diagnostics and therapy (<i>Endorsed by the European Journal of Endocrinology</i>)	S23.1–S23.3
Androgens and disease progression in prostate cancer	S24.1–S24.3
Challenges in pituitary tumours	S25.1–S25.3
Towards the bionic pancreas: will the journey end?	S26.1–S26.3
Thyroid cancer: new development in diagnosis and treatment (<i>Endorsed by the European Journal of Endocrinology</i>)	S27.1–S27.3
Hormones and immunity in pregnancy	S28.1–S28.3
Management of endocrine transition	S29.1–S29.5

DEBATE

How to manage hyponatraemia according to guidelines? D1.1–D1.2

MEET THE EXPERT SESSIONS MTE1–MTE17

EDUCATIONAL WORKSHOP

Practical publishing advice EW1.1–EW1.6

EUROPEAN YOUNG ENDOCRINOLOGISTS

Sex, drugs and rocking hormones EYES1.1–EYES1.6

ENDOCRINE NURSING

The journey of the patient with obesity: multidisciplinary care approach EN1.1–EN1.3

Professional development, poster presentations and networking EN2.1–EN2.6

Meet the Nurse Expert EN3.1–EN3.3

ORAL COMMUNICATIONS

Adrenal 1 OC1.1–OC1.5

Reproduction OC2.1–OC2.5

Calcium, vitamin D and bone OC3.1–OC3.5

Diabetes OC4.1–OC4.5

Steroids, developmental and paediatric endocrinology OC5.1–OC5.5

Thyroid OC6.1–OC6.5

Neuroendocrinology and pituitary-basic OC7.1–OC7.5

Endocrine tumours OC8.1–OC8.5

Adrenal 2 OC9.1–OC9.5

Nuclear receptors and signalling OC10.1–OC10.5

Obesity OC11.1–OC11.5

Pituitary– Clinical OC12.1–OC12.5

GUIDED POSTERS

Adrenal GP.01.01–GP.01.08

Adrenal GP.02.01– GP.02.08

Adrenal GP.03.01–GP.03.08

Steroids GP.04.01–GP.04.09

Developmental and paediatric endocrinology GP.05.01–GP.05.10

Reproduction: Female and PCOS GP.06.01–GP.06.08

Reproduction: Female and other GP.07.01–GP.07.07

Reproduction: Male and endocrine disruptors GP.08.01–GP.08.08

Nuclear receptors and signalling GP.09.01–GP.09.08

Calcium, Vitamin D and Bone GP.10.01–GP.10.10

Calcium, Vitamin D and Bone GP.11.01–GP.11.09

Diabetes and obesity - Translational diabetes GP.12.01–GP.12.07

Diabetes and obesity–Translational cardiovascular and obesity GP.13.01–GP.13.08

Diabetes and obesity–Clinical diabetes GP.14.01–GP.14.08

Diabetes and obesity–basic GP.15.01–GP.15.07

Diabetes and obesity–Clinical obesity and cardiovascular GP.16.01–GP.16.08

Pituitary–Neuroendocrinology and central salt regulation GP.17.01–GP.17.09

Pituitary–Basic and IGF-1 GP.18.01–GP.18.09

Pituitary–Acromegaly GP.19.01–GP.19.10

Pituitary - Hypopituitarism GP.20.01–GP.20.09

Pituitary - Diagnosis of Cushing’s disease GP.21.01–GP.21.06

Pituitary–Therapy of Cushing’s disease GP.22.01–GP.22.07

Thyroid - diagnosis GP.23.01–GP.23.09

Thyroid–genetics GP.24.01–GP.24.08

Thyroid - nodule GP.25.01–GP.25.07

Thyroid - hypothyroidism	GP.26.01–GP.26.10
Thyroid - hyperthyroidism and treatment	GP.27.01–GP.27.08
Endocrine tumours and neoplasia - NETS	GP.28.01–GP.28.09
Endocrine tumours and neoplasia - Adrenal Tumour	GP.29.01–GP.29.07
Endocrine tumours and neoplasia - General	GP.30.01–GP.30.07

EPOSTER PRESENTATIONS

Adrenal cortex	EP1–EP94
Steroids, development and paediatric endocrinology	EP95–EP130
Reproduction, endocrine disruptors and signalling	EP131–EP222
Calcium and Vitamin D metabolism	EP223–EP318
Diabetes (pathiophysiology & epitemiology)	EP319–EP398
Diabetes (complications & therapy)	EP399–EP541
Obesity and cardiovascular endocrinology	EP542–EP649
Pituitary: basic and neuroendocrinology	EP650–EP711
Pituitary: clinical	EP712–EP832
Thyroid cancer	EP833–EP922
Thyroid (non-cancer)	EP923–EP1082
Endocrine tumours	EP1083–EP1151
Clinical Cases–Pituitary/Adrenal	EP1152–EP1246
Clinical Cases–Thyroid/Other	EP1247–EP1347
Endocrine nursing	EP1348–EP1353

INDEX OF AUTHORS

E-Posters

Conclusions

An oral dose of 600 000 IU of cholecalciferol in HIV-1 postmenopausal women rapidly increases 25(OH)D and 1,25(OH)₂D levels reducing PTH levels, regardless of the presence of PIs in the cART scheme.

DOI: 10.1530/endoabs.37.EP293

EP294

May the polymorphism of low molecular weight protein tyrosine phosphatase modulate metabolic and bone remodelling parameters associated with osteoporosis?

Joana Freitas^{1,2}, Cristina Monteiro³, Ana Paula Barbosa^{2,4}, Fátima Batista³, Maria José Laires³, Manuel Bicho^{1,2} & Mário Rui Mascarenhas^{2,5}

¹Institute for Scientific Research Bento Rocha Cabral, Lisbon, Portugal; ²ISAMB, FMUL, Lisbon, Portugal; ³CIPER, FMH-UL, Lisbon, Portugal; ⁴Clinic of Endocrinology, Diabetes and Metabolism, Lda, Lisbon, Portugal; ⁵Department of Endocrinology, Diabetes and Metabolism, HSMaria-CHLN, Lisbon, Portugal.

Aims

To study the association of protein tyrosine phosphatase (LMW-PTP/ACPI) polymorphism with bone mineral density and metabolic parameters of bone remodelling.

Methods

BMD (g/cm²) was measured by DEXA in 760 subjects: 448 normal BMD (359F/89M; 49.7 ± 12.9 years; 30.2 ± 5.4 kg/m²) and 312 osteoporosis (265F/47M; 63.9 ± 10.4 years; 27.16 ± 4.4 kg/m²). Metabolic bone remodelling parameters were analyzed: LDL, HDL, total cholesterol, triglycerides, HOMA, alkaline phosphatase (AP), and osteocalcin. ACPI activity was measured by spectrophotometry. ACPI polymorphism was evaluated by PCR.

Results

Association was found between the genetic polymorphism of ACPI and its enzymatic activity with higher values for genotypes AC+BC, intermediate values for BB and lower values for AA+AB. Osteoporosis: i) increased LDL, total cholesterol, AP, osteocalcin and ACPI, and decreased HOMA; ii) association between genotypes BB+BC+AC and increased total cholesterol, LDL, and ACPI; and iii) positive correlation between AP and LDL, total cholesterol, and osteocalcin. Normal BMD: i) association between genotypes BB+BC+AC (intermediate and higher ACPI activity) and increased ACPI and decreased AP and ii) positive correlation between AP and osteocalcin and HOMA. Only correlations of AP with LDL and total cholesterol remained significant when analyzed separately AA+AB individuals.

Conclusion

In osteoporosis, ACPI polymorphism appears to modulate some metabolic parameters associated with a decrease in BMD, including total cholesterol, LDL, and ACPI activity.

DOI: 10.1530/endoabs.37.EP294

EP295

Pancreatitis in familial hypocalcaemic hypercalcaemia

Iulia Potorac¹, Olivier Malaise², Adrian Daly¹ & Albert Beckers¹

¹Department of Endocrinology, CHU de Liège, University of Liège, Liège, Belgium; ²Department of Rheumatology, CHU de Liège, University of Liège, Liège, Belgium.

Familial hypocalcaemic hypercalcaemia (FHH) is a characteristically asymptomatic condition that is caused principally by calcium sensing receptor gene (CASR) mutations and less frequently by GNA11 or AP2S1 mutations. We report a case of recurrent symptomatic pancreatitis in an FHH patient. The 17-year-old patient was hospitalized with abdominal pain and raised pancreatic enzymes due to acute pancreatitis. The only predisposing factor on investigation was a very elevated serum calcium level (3.3 mmol/l; NR: 2.15–2.60). This was associated with concomitantly moderately elevated PTH (33 ng/l; NR: 4–26), normal 25-OH vitamin D (44 ng/ml; NR: 30–80), elevated 1,25(OH)₂ vitamin D (133 pg/ml; NR: 23–109), and undetectable urinary calcium. Family history revealed that the patient's grandmother was also known to suffer from hypocalcaemic hypercalcaemia, and that hypercalcaemia had been found in the patient's mother, uncle, brother and sister. CASR sequencing revealed the patient (and family members) to be heterozygous for a R185Q mutation, previously suggested to be a dominant

negative mutation and leads to higher calcium levels than other known CASR mutations. Cinacalcet treatment lowered serum calcium to 2.95 mmol/l and the patient has not presented new pancreatitis episodes.

DOI: 10.1530/endoabs.37.EP295

EP296

Giant parathyroid adenoma with severe hypercalcaemia: case report

Cristina Spiroiu, Aurelian Emil Ranetti & Claudiu Nistor
Central University Military Hospital 'Dr Carol Davila', Bucharest, Romania.

Introduction

Parathyroid adenomas are the main cause of primary hyperparathyroidism. They are usually small – weighing < 1 g – and not easy to find – requiring meticulous imaging studies for localisation. Giant adenomas are uncommon; large tumours and high levels of PTH raise the suspicion of parathyroid malignancy.

Case presentation

A 68-year-old female presented in our clinic with polydipsia, poliuria, nausea, weight loss, and extreme muscular weakness – she wasn't able to walk – and depressive mood. Clinical exam revealed dehydration and right cervical mass. Calcium was 21 mg/dl and PTH was 2238 pg/ml. The patient was also vitamin D deficient – 25OH vitamin D 14 µg/l. Radiographic study showed fracture of the first lumbar vertebra, CT scan showed multiple osteolytic areas of the skull. Osteodensitometry demonstrated osteoporosis (lumbar spine T score –2.9 s.d. and distal radius T score –6.7 s.d.). Ultrasonography revealed a hypoechoic inhomogeneous mass, 38/30/45 mm, laterally and caudally to the right thyroid lobe. Parathyroid scintigraphy (99Tc-MIBI) demonstrated a large area of high uptake in that region. The patient received intravenous fluids, loop diuretic, i.v. bisphosphonate (zoledronate) and calcitonin to reduce the level of calcium, then she was successfully operated. Calcemia dropped after surgery and it was managed with i.v. calcium and alpha calcidol. Mild hypocalcaemia persisted for more than 6 months thereafter and so did the high levels of PTH, that raised to 506.5 pg/ml, then returned to normal – the hungry bones syndrome. The pathologic diagnosis was benign parathyroid tumour – parathyroid adenoma.

Conclusions

This is a rare case of giant parathyroid adenoma. The peculiarities of the case are the size of the tumour, the very high level of calcium and PTH – suggesting a malignant tumour, and the persistence of high levels of PTH and hypocalcaemia months after surgery.

DOI: 10.1530/endoabs.37.EP296

EP297

Primary hypoparathyroidism is common in adult patients with β-thalassaemia and protect patients from osteoporosis

Anna Ansaloni¹, Francesca Ferrara³, Chiara Diazzi^{1,2}, Antonello Pietrangelo³, Manuela Simoni^{1,2} & Vincenzo Rochira^{1,2}

¹Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy; ²Azienda USL of Modena, Modena, Italy; ³Unit of Internal Medicine, Research Center 'Mario Coppi', University Hospital Policlinico, Modena, Italy.

Introduction

β-thalassaemia (βT) is associated to several endocrine abnormalities mainly due to iron overload. With the increase in βT-patients life expectancy, due to progresses in iron chelation therapy, more patients enter into adulthood than in the past and the prevalence of endocrine diseases is being reconsidered. The aim of the study is to investigate the prevalence of primary hypoparathyroidism (pHPT) in adult βT-patients and to characterize the relative clinical phenotype with particular regard to bone health.

Methods

We enrolled 26 adult patients with major or intermedia βT (12M and 14F; mean age ± s.d. of 38.1 ± 7.5 years). Serum PTH, 25-hydroxyvitamin D (25OHD), calcium, phosphorous, albumin, bone turnover markers, and bone mineral density (BMD) by dual-energy X-ray absorptiometry (Hologic) at lumbar and femoral site were measured.

Results

pHPT (PTH < 15 pg/ml) was found in seven of the 26 patients (27%). Of them, four patients (57%) had hypocalcemia and two were on chronic calcium therapy. Lumbar BMD was significantly higher in patients with pHPT ($0.884 \pm 0.189 \text{ g/cm}^2$) than in patients without pHPT ($0.731 \pm 0.124 \text{ g/cm}^2$) ($P=0.023$). No significant difference was found in femoral BMD, even though a trend for higher BMD was present in pHPT (0.704 ± 0.117 vs $0.670 \pm 0.143 \text{ g/cm}^2$ in pHPT and no-pHPT respectively) ($P=0.578$). The prevalence of osteoporosis was higher in patients without pHPT (68%) than in patients with pHPT (29%). Two patients had a history of bone osteoporotic fractures and both of them did not present pHPT. Bone turnover markers were no different in the two groups.

Conclusions

The prevalence of pHPT in adult bT-patients is higher if compared to that observed in pediatric bT-patients, the latter ranging from 8 to 11%. Moreover we found an higher prevalence of pHPT compared to that reported in literature on adult bT patients. As expected, pHPT seems to exert a protective role on the development of osteoporosis in these patients.

DOI: 10.1530/endoabs.37.EP297

EP298**Renal calcification in hyperparathyroid patients treated with calcium and vitamin D: can biochemistry help?**Sivatharshya Pathmanathan¹, Scott Tolhurst², Emma Illingworth¹, Claire Higham¹, Peter Trainer¹ & Phillip Monaghan²¹Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK; ²The Christie Pathology Partnership, The Christie NHS Foundation Trust, Manchester, UK.**Introduction**

Hypoparathyroidism is most commonly observed following neck surgery and is characterized biochemically by deficient parathyroid hormone (PTH) and hypocalcaemia alongside hyperphosphataemia and reduced 1,25-dihydroxyvitamin D. Standard treatment with oral calcium and vitamin D aims to maintain serum calcium within the low-normal range whilst avoiding hypercalciuria due to over replacement. However, concerns remain over the presence of hypercalciuria and the associated risk of renal calcification.

Aim

To assess whether serum and urine biochemical parameters are associated with the presence of renal calcification in hypoparathyroid patients on Alfacalcidol therapy.

Method

A 12-month audit of the laboratory database was undertaken of paired requests for 24-h urine calcium (24 h-Ca), spot calcium:creatinine ratio (Ca:Creat), serum calcium, phosphate, urea, and creatinine. A review of case notes was performed to confirm aetiology of hypoparathyroidism, Alfacalcidol dose and results of renal ultrasound scan (USS).

Results

A total of 34 patients were identified as having hypoparathyroidism and receiving Alfacalcidol therapy. 24 h-Ca and Ca:Creat were not normally distributed, however significant associations were found between 24 h-Ca and Ca:Creat when log-transformed (linear regression β -coefficient=0.64; 95% CI 0.36–0.92; $P<0.001$, $\beta=0.63$). 17 patients had documented hypercalciuria evidenced by elevated 24 h-Ca (five patients), Ca:Creat (eight patients), or both (four patients). 13 patients had undergone renal USS; four had evidence of renal calcification. Interestingly, these four patients each had an elevated Ca:Creat, in contrast with only one patient having elevated 24 h-Ca. No patient had hypercalcaemia. However, 20 patients had low, or low-normal serum adjusted calcium (Ca < 2.2 mmol/l); nine of these patients having documented hypercalciuria evidenced by an elevated 24 h-Ca (78% of patients) or Ca:Creat (89% of patients).

Conclusion

Ca:Creat appears a sensible and convenient marker for the follow-up of patients on long term Alfacalcidol therapy to determine associated risk of renal calcification.

DOI: 10.1530/endoabs.37.EP298

EP299**Parathyroid tissue in ectopic thyroid tissue**João Silva, Catarina Ivo, Mafalda Marcelino, Dolores Passos, Hélder Simões, Luís Lopes & João Jacome de Castro
Armed Forces University Hospital, Lisbon, Portugal.**Introduction**

Postmortem studies have shown that a fifth parathyroid gland may be present in about 5% of patients with hyperparathyroidism. 1% of parathyroid glands are located in thyroid tissue. There's a prevalence of 7–10% of thyroid ectopic tissue. Case report

A 53-year-old male, submitted to bilateral nephrectomy due to a Grawitz tumour at the age of 25. Under haemodialysis since then (with a rejected renal transplant in the past), he was recently referred to our department with a tertiary hyperparathyroidism diagnosis. Treated intra-hemodialysis with alfacalcidol 0.25 µg and cinacalcet. Analytically had a PTH 1604 pg/ml, calcium 9.5 mg/dl, phosphorus 5.6 mg/dl, and creatinine 11.4 mg/dl. Cervical ultrasound did not identify parathyroid gland and thyroid scintigraphy suggested parathyroid adenoma in the bottom right. PET-scan showed bone lesions suggestive of brown tumours. The patient was submitted to surgery and has removed four parathyroid glands (9–20 mm) with an histology of 'nodular hyperplasia of the parathyroid'. Was also removed a fifth nodule located in the lower left region with 9 mm, described as 'focus of parathyroid in parenchyma thyroid (intra-thyroid parathyroid?)'. Three months after surgery he's treated with 1 g of calcium carbonate (3+3+3) and 0.25 µg calcitriol (1+0+1), with PTH 139 pg/ml, calcium 8.2 mg/dl, and phosphorus 2.6 mg/dl.

Conclusions

In this patient despite scintigraphy suspicion of a functioning parathyroid adenoma, since it is a tertiary hyperparathyroidism, we chose surgical exploration with resection of all parathyroid glands. It was found a fifth focus of parathyroid tissue within an ectopic thyroid tissue. This case presents the association of three relatively rare situations: supernumerary parathyroid gland, in thyroid tissue in an ectopic location.

DOI: 10.1530/endoabs.37.EP299

EP300**Anti-diabetic treatment as an additional factor in a FRAX based evaluation of osteoporotic fracture risk**Maria P Yavropoulou, Athanasios Mousiolis, Vasiliki Kolokouri, Pelagia Kolimbianaki, Athina Dimitriou, Petros Papalexis, Michael Daniilidis & Kalliopi Kotsa
Department of Endocrinology and Diabetes, AHEPA University Hospital, Thessaloniki, Greece.**Background**

The present study is designed to assess the incidence of osteoporotic fractures and the associated risk factors and particularly those used to predict the 10-year fracture risk in FRAX score based on data gathered in general practitioner's records of rural Greece.

Patients and methods

We conducted a retrospective analysis of all patients with osteoporosis presented between October 2013 and December 2014. Data from medical records including gender, age, previous history of low energy fractures (spine, and distal radius), past medical history, and medication use with specific reference to treatment with bisphosphonates and glucocorticoids were obtained. Patients with metabolic bone disease other than osteoporosis were excluded from the final analysis.

Results

One hundred and sixty seven patients (127 women and 40 men) aged between 44 and 90 years old were included in the final analysis. Twenty-seven percent of the study population ($n=45$) had sustained a low energy fracture and only 43% of them had received anti-osteoporosis treatment. Regarding concomitant medications only anti-diabetic treatment was significantly associated with the presence of osteoporotic fracture ($F=4.260$, $P=0.042$), and had a considerable effect on the 10-year risk of major osteoporotic and hip fractures in drug-naïve patients.

Conclusion

Anti-diabetic treatment should be taken into consideration when evaluating fracture risk in osteoporotic patients.

DOI: 10.1530/endoabs.37.EP300

EP301**A giant parathyroid cyst manifesting with a neck mass and hypercalcaemic crisis**Fotini Adamidou, Christina Manani, Vassilis Champidis, Panagiotis Anagnostis, Apostolos Kamaroudis & Marina Kita
Hippokraton General Hospital, 49 Konstantinoupoleos Street, Thessaloniki 54642, Greece.

Author Index

- Abbara, A EP55
 Abbas, J EP1133
 Abbas, M EP420 & EP510
 Abbasoglu, SD EP9
 & EP948
 Abbassy, M EP779
 Abbondanza, C EP1147
 Abd El Aziz, A EP421
 Abd El Aziz, M EP494
 Abd El Gaffar, N EP402
 Abd El Mageed, Y EP510
 Abd-El Kareem, M EP837
 Abd-El Razek, S EP837
 Abd-el-Salam, RF EP229
 Abdalla, A EP275
 Abdallah, NB EP1064,
 EP1065 & EP929
 Abdelaziz, MF EP1001
 Abdelrazek, S EP931
 Abdelsalam, MM EP1000
 & EP1001
 Abderahmane, SA EP1170
 Abderrahmane, SA
 EP1275
 Abdo, R EP402
 Abdul Shakoore, SAKK
 EP1270
 Abegg, K EP515
 Abes, H EP1108
 Abeygunasekara, S
 GP.17.08
 Abid, M EP1239, EP534
 & EP85
 Abigél, F EP67
 Abraitienne, A EP726
 Abramenko, A EP790
 Abreu, A EP807
 Abribat, T OC11.4
 Abushady, M EP456
 & EP510
 Acar, K EP1339
 Acar, U EP517
 Ach, K EP418, EP533
 & GP.16.06
 Acha-Pérez, J EP1342
 Acharya, J EP1347
 & EP55
 Acikalin, M EP482
 Ackermans, M GP.11.05
 Acosta-Calero, C EP1006
 & EP1249
 Acs, N EP314
 Acs, O EP314
 Adamidou, A GP.17.03
 Adamidou, F EP291,
 EP301, EP69 & EP917
 Adams, K EN3.1
 Adamska, A EP816,
 GP.06.04 & GP.06.08
 Adamska, E GP.12.03
 Adamski, J GP.05.04
 Adane, S EP1110
 Adas, M EP448 & EP932
 Adrados, M GP.28.09
 Adrian, I EP1046
 Aerden, D EP511
 Aerts, E GP.13.02
 Afonin, A EP537
 Afonso, A EP691
 Aftab, AR EP396
 Agapito, A EP1216,
 EP1222, EP1297,
 EP290 & EP691
 Aggarwal, A GP.01.08
 Aggarwal, N EP1167
 & EP250
 Aggarwal, R GP.01.08
 Aggelidou, E GP.05.09
 Agha, A EP1226, EP1230,
 EP744, EP759, EP885,
 GP.04.02, GP.04.07
 & OC12.1
 Aghajanova, Y EP1087
 & GP.12.02
 Agota, K EP292
 Agredos, EP549
 Aguilar-Diosdado, M
 EP1181, EP360,
 EP465, EP466, EP467,
 EP573, EP875
 & GP.16.04
 Aguirre, M EP1040
 & EP737
 Ahabab, S EP1054, EP1335
 & EP8
 Ahern, T EP574 & EP575
 Ahern, TB GP.08.01
 Ahmad, A EP107, EP172,
 EP768 & GP.08.08
 Ahmed, A EP1302 & EP35
 Ahmed, M EP349, EP78,
 EP886 & EP888
 Ahmed, SF MTE16
 Ahmeti, E EP1300
 Ahn, CW EP442
 Ahn, KJ EP461 & EP585
 Ai, L EP376
 Aigbirhio, F OC1.4
 Aigelsreiter, A EP554
 Ajduk, M EP638
 Ajjan, R GP.16.05
 Akalin, A EP941
 Akarsu, E EP1060
 & EP880
 Akasheva, D GP.12.05
 Akavarapu, S EP1223,
 EP1347 & EP55
 Akbas, F EP964
 Akbulut, S EP1192
 Akcan, E EP482
 Akcicek, F EP131, EP319,
 EP321 & EP406
 Akdemir, O EP913
 Akgul, OF EP49, EP502
 & EP506
 Akin, F EP1038, EP1261,
 EP14, EP236 & EP237
 Akin, S EP309
 Akinci, B EP342 & EP345
 Akinci, G EP345
 Akiyama, Y EP1255
 Akkaya, ZY EP391
 Akker, S EP1149
 Akker, SA EP1148 & EP92
 Akkus, G EP1183 & EP31
 Akram, M EP107, EP172,
 EP768 & GP.08.08
 Aksentic, V EP266
 Aksit, M EP219
 Aksoy, N EP1060
 Aksoy, S EP978
 Aksoy, SY EP1174
 Aksu, C EP997
 Aksun, S EP139
 Aktürk, M EP802 & EP961
 Aktan, AH EP11
 Aktas, A EP972
 Akturk, M EP30, EP912,
 EP913, EP978
 & EP982
 Akulkina, L EP654
 Akyay, OZ EP760 & EP761
 Akyay, Z EP7, EP722
 & EP845
 Akyel, F EP547
 Akyel, S EP547
 Al Ahmadi, J EP349
 Al Masroori, M EP152
 Al-Asmakh, M OC5.1
 Al-Ezzi, M EP1010
 & EP837
 Al-Maramhy, H EP567
 Al-Sawalhi, S EP567
 Al-Shali, K EP349
 Al-Wakeel, S EP229
 Alagüney, E EP128
 Alagüney, ME EP548
 Alagol, F EP9 & EP903
 Alapi, T EP151
 Alarслан, P EP1048
 & EP339
 Albán, F GP.23.09
 Albani, A EP1137 & EP75
 Albani, M GP.05.09
 Albayrak, D EP887
 Albero, A EP870
 Albiger, N GP.21.01
 & GP.28.01
 Albin, M EP36
 Albu, A EP123, EP197,
 EP213, EP243
 & EP634
 Albu, D EP213
 Alcaide, J EP340
 Alcalá, BB EP261
 Alcorta, A EP425
 Aldersy, N EP403
 Aldibbiat, A EP1175
 Aleksandrov, Y EP1103
 Alesse, E EP694
 Aletras, V EP471
 Alevizaki, M EP728,
 GP.23.08 & GP.27.03
 Alex, S EP558
 Alexandra, M EP501
 Alexandra, S EP501
 Alexandraki, K EP1143,
 EP1146, EP373,
 EP697, EP704
 & EP754
 Alexandrescu, D EP915
 Alexiu, F EP1144
 Alfaro, JJ EP1039 & EP999
 Alfonso, AMP EP789
 Alfonso, FJG EP1037
 Alghamdi, A EP349
 Algun, E EP11 & EP417
 Alhambra-Expósito, MR
 EP695
 Alhozali, A EP349
 Alhumaidi, N EP403
 Ali, LA EP108, EP110,
 EP1108, EP1111,
 EP42, EP43, EP44
 & EP50
 Alissa, E EP542
 Aljahdali, A EP349
 Aljefery, M EP1072
 Alkhalaf, F EP403

- Robledo, M GP.23.07 & S12.1
 Robles, M EP860
 Roca-Rodríguez, MM EP1262
 Rocca, MS EP221 & EP222
 Rocha, A EP173
 Rochira, V EP182, EP210 & EP297
 Rockich, K EP54
 Rodic, G EP1141
 Rodríguez, JCR EP433
 Rodríguez, MDM EP767
 Rodríguez-Muñoz, A EP1059 & GP.28.09
 Rodríguez-Tanty, C EP437
 Rodrigo, EP EP330
 Rodrigues, D EP1303, EP388, EP772, EP778 & EP819
 Rodrigues, E EP1263, EP1299 & EP545
 Rodrigues, F EP1296 & GP.25.03
 Rodriguez, AS EP1061
 Rodriguez, S OC1.2
 Rodriguez, SA EP707
 Roelfsema, F OC5.5
 Roemmler-Zehrer, J EP791
 Roepke, Y GP.05.04
 Rogatko, I EP688 & GP.07.07
 Rogers, B GP.04.07
 Rogowicz-Frontczak, A EP363
 Rogowski-Lehmann, N EP312
 Rojbi, I EP1212
 Rojo-Martínez, G EP1002
 Roldán-Caballero, P EP875
 Roldan, F EP701
 Roli, L OC4.3
 Rollenhagen, A EP658
 Romãozinho, C EP520
 Romaldini, J EP1032 & EP1066
 Romanousky, A EP601
 Romanowicz, T EP1231
 Romantsova, T OC11.5
 Rombouts, S GP.21.03
 Romero, C EP1326
 Romero-Lluch, AR EP895
 Romero-Perez, S EP1030
 Romero-Ruiz, A GP.13.04 & OC7.4
 Romijn, J EW1.4 & GP.01.07
 Roncero-Martin, R EP271
 Ronchi, C GP.02.03 & OC9.5
 Ronchi, CL EP1131 & GP.29.01
 Roque, C EP541
 Rorive, S EP1172
 Rosa, CD EP1147
 Rosca, R EP212
 Rose, IT GP.05.02
 Roseiro, A EP509
 Rosendaal, F GP.11.08
 Rosendo, C EP360
 Rosenwald, A EP1131 & GP.29.01
 Roseto, CdLd EP1132
 Roshdy, N EP494
 Rosiek, V EP1084
 Roskosz, J EP904
 Ross, I EP24
 Ross, R OC9.2 & OC9.3
 Ross, RJ GP.03.02
 Rossi, DS EP247
 Rossi, R EP868
 Rossi, S EP858 & GP.24.02
 Rossi, V EP1147
 Rossing, P S2.1
 Rossodivita, AN EP103
 Rossokha, Z EP382
 Rossum, Ev S23.3
 Rosta, E GP.05.02
 Rostomyan, L GP.19.04, OC12.3, OC12.5 & S11.1
 Rostrup, E EP1350
 Rosu, N EP1187
 Rothman, J OC3.5
 Rotondi, S EP693 & EP694
 Roudaut, N EP833
 Roumes, H EP684 & GP.17.01
 Rourke, JL GP.13.01
 Roussaki, P EP754
 Roux, Cl EN1.2 & GP.14.05
 Rovira, A EP661 & GP.18.04
 Rovira, E EP1296
 Rozhinskaya, L EP1091, EP1185, EP685, EP689, EP705, EP777, GP.02.08 & GP.22.07
 Rubanyi, G GP.15.01
 Rubio, MA EP455
 Ruchala, M EP625
 Ruchala, M EP1120, EP1233, EP1274, EP1316, EP792, EP809, EP955 & EP956
 Rudakova, J EP351, EP352 & EP374
 Rudzinska, M GP.24.01
 Ruffilli, I EP867
 Ruiz, G EP860
 Ruiz-Gracia, T EP672, EP673 & GP.03.05
 Ruiz-Pino, F GP.13.04 & OC7.4
 Ruiz-Ruiz, F EP1330 & EP375
 Runkle, I EP672, EP673 & GP.03.05
 Rusalenko, M EP328
 Rusina, R GP.18.02
 Russillo, A EP247
 Rusu, C EP635 & EP824
 Rutishauser, J EP796
 Rutkowska, A EP209
 Rutkowska, J EP362
 Ruttten, E EP1352
 Rutter, M OC2.4
 Ruza, I EP1313
 Ruzsa, B EP733
 Ryan, A GP.10.03
 Ryan, K EP481
 Ryan, M GP.01.02
 Ryanputra, D EP786, EP854 & EP859
 Rybalchenko, V EP852
 Rybicka, B GP.30.04
 Rylander, L GP.18.04
 Rymaszewska, J EP690
 Ryu, OH EP367
 Sá, J EP124
 Sánchez, C EP1044
 Sánchez-Malo, C EP895
 Sánchez-Sánchez, R EP1127
 Sönmez, B EP918
 Saad, A EP494
 Saada, B EP1212
 Saatov, T EP570
 Saavedra, A EP1224, EP1243, EP1299 & EP561
 Sabadková, D EP492
 Sabanero, M GP.05.10
 Saber, SEM EP181
 Sablón-Carrazana, M EP437
 Sabry, I EP494
 Sabt, A EP403
 Saccardi, R EP285
 Sachan, A GP.01.08
 Sacher, A EP909
 Sacikara, M EP908
 Sacvhenko, AA EP653
 Sadoul, J-L GP.30.01
 Saeed, A EP22
 Saeed, N EP513
 Saenz, MSG EP767
 Saez-de Parayuelo, MV GP.03.05
 Safer, M EP1111
 Sager, CR EP116
 Sagiv, N EP721
 Saglar, E EP1329
 Sah, B EP281
 Sahdev, A EP1148 & EP1149
 Sahdeve, A EP92
 Sahin, AB EP919
 Sahin, I EP507
 Sahin, M EP1106, EP1107, EP1293, EP177, EP187, EP278, EP489, EP49, EP502, EP506, EP507, EP52, EP617, EP900, EP951 & OC3.4
 Sahin, O EP417
 Sahin, OZ EP11
 Sahin, SB EP11 & EP417
 Sahli, H EP305
 Sahu, S GP.01.08
 Saikia, UN OC4.5
 Sainz, RM GP.30.03
 Sakali, A-K EP699 & EP700
 Sakiz, D EP1016
 Sala, E EP806 & GP.19.02
 Salah, DB EP251
 Salah, HM EP530
 Salak, B GP.26.01
 Salam, R EP1008
 Salama, AF EP181
 Salamon, A EP292
 Salas, JJC EP261
 Salazar, L EP985
 Salehmohamed, MR EP1238 & EP84
 Salehmohamed, R GP.17.07
 Salek-Haddadi, A EP135
 Saler, T EP1054
 Salerno, M S4.1
 Salgado, LR EP811 & GP.22.04
 Salim, T EP759
 Salma, A EP1083